DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects
- PMID: 16455265
- DOI: 10.1016/j.nbd.2005.12.006
DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects
Abstract
Among the various phenotypes seen in Down syndrome (DS), mental retardation is the most common and most debilitating condition suffered by individuals with DS. The DYRK1A gene on human chromosome 21q22.2 encodes a subfamily of protein kinases that displays dual substrate specificities and is known to play a critical role in neurodevelopment. To study DS mental retardation, we have generated transgenic mice that contain only one copy of the complete human DYRK1A gene in a bacterial artificial chromosome. The transgenic mice showed significant impairment in hippocampal-dependent memory tasks in a Morris water maze. Interestingly, we observed shifts in both long-term potentiation and long-term depression, which suggests a role for DYRK1A in bidirectional synaptic plasticity. These mice represent the most clinically relevant DYRK1A mouse model to date and provide us a valuable tool for the in vivo study of mechanisms that underlie the learning and memory deficit in DS.
Similar articles
-
Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome.Neurobiol Dis. 2013 Apr;52:117-27. doi: 10.1016/j.nbd.2012.11.017. Epub 2012 Dec 5. Neurobiol Dis. 2013. PMID: 23220201
-
Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease.J Neurochem. 2008 Mar;104(5):1333-44. doi: 10.1111/j.1471-4159.2007.05075.x. Epub 2007 Nov 14. J Neurochem. 2008. PMID: 18005339
-
Putative therapeutic agents for the learning and memory deficits of people with Down syndrome.Bioorg Med Chem Lett. 2006 Jul 15;16(14):3772-6. doi: 10.1016/j.bmcl.2006.04.042. Epub 2006 May 12. Bioorg Med Chem Lett. 2006. PMID: 16698266
-
Comparative plasticity of brain synapses in inbred mouse strains.J Exp Biol. 2006 Jun;209(Pt 12):2293-303. doi: 10.1242/jeb.01985. J Exp Biol. 2006. PMID: 16731805 Review.
-
Mental retardation and associated neurological dysfunctions in Down syndrome: a consequence of dysregulation in critical chromosome 21 genes and associated molecular pathways.Eur J Paediatr Neurol. 2008 May;12(3):168-82. doi: 10.1016/j.ejpn.2007.08.010. Epub 2007 Oct 22. Eur J Paediatr Neurol. 2008. PMID: 17933568 Review.
Cited by
-
Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics.Neural Plast. 2012;2012:171639. doi: 10.1155/2012/171639. Epub 2012 Jul 12. Neural Plast. 2012. PMID: 22848846 Free PMC article. Review.
-
Creation and characterization of BAC-transgenic mice with physiological overexpression of epitope-tagged RCAN1 (DSCR1).Mamm Genome. 2013 Feb;24(1-2):30-43. doi: 10.1007/s00335-012-9436-9. Epub 2012 Oct 25. Mamm Genome. 2013. PMID: 23096997 Free PMC article.
-
Re-Arranging the Puzzle between the Amyloid-Beta and Tau Pathology: An APP-Centric Approach.Int J Mol Sci. 2023 Dec 23;25(1):259. doi: 10.3390/ijms25010259. Int J Mol Sci. 2023. PMID: 38203429 Free PMC article. Review.
-
DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome.Front Behav Neurosci. 2016 Jun 3;10:104. doi: 10.3389/fnbeh.2016.00104. eCollection 2016. Front Behav Neurosci. 2016. PMID: 27375444 Free PMC article. Review.
-
Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes.Pharmacol Biochem Behav. 2022 Jun;217:173404. doi: 10.1016/j.pbb.2022.173404. Epub 2022 May 14. Pharmacol Biochem Behav. 2022. PMID: 35576991 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials